your going to see the stock bounce back. it's down 12%. keep it on a short leash. and of course the beard. ♪ too sexy >> grasso's beard. back to you, mel. >> i'm see you tomorrow at 5:00r "fast money." "mad money" starts right now. \s. my mission is simple -- to make you money. i'm here to level the playing field for all investors. there's always a bull market somewhere, and i promised to help you find it. "mad money" starts now. hey, i'm cramer. welcome to "mad money." well can um to cramerica. my job is not just to entertain, but to teach and put in perspective. so call me at 1-800-74 p-cnbc or tweet me @jimcramer. when we look back at the quarter we just laid to rest, it was the tale of two halves.

the first half called people to run screaming from the stock market. the second half produced some fabulous gains. even as we pull back today, the dow dipping 32 points, s&p declining, nasdaq actually bucking the trend, advancing marginally. yes, i phrased it like great expectations. where was the worst of times and best of times one one quarter. i want to do some teaching here, and not just about english l illustrate t the lesson of this winter despair flosh has a spring of hope. nor one with no earnings prospects, but a company that historically has hung in there? you almost always get a better chance to sell than into the vortex of panic. that causes so many investors to lose their heads at the worst possible time. let's start with caterpillar. the giant machinery company has had such a hard go of it as of late.

at the end of january they reported a loss of 15 cents versus 1.35 profit the year before, but if you looked unthe hood, they taken a huge restructuring charge. at the time, ceo doug objectorhelmen said cost restructuring and operational executions are helping the company while sales remain under pressure from weak commodity prices and slowing economic growth in developing countries. but he aded, quote -- our balance sheet is strong, our product quality remains at high levels. we gain market position for machines for the fifth year in a row. inventory levels are in decline and we are well positioned looking forward to 2016. he also made it clear that the recently raised dividend, which gave you a yield of almost 6% was a priority to be paid. that stock plunged to $57, and

do you know that since then it hasn't stopped soaring, closing at $76 and change. in let roe spect, it was so easy to sell back then, the dividend wasn't being covered even as cat's gargantuan cash flow made it look safe. the dollar -- iron orr and copper prices have been plummeted, and the chinese stock market fell in two months' time. in the keynesian terms. that low was pretty much for every single commodity. despite the overwhelming negative back drop, it was a time to buy buy buy. the toughest move would have gone the smartest one to take. then there's apple. you look at this past quarter, you see a stock, you see a stock that went from $105 to $93 and

change before rebounding back to $109 after trading as high as 132 last summer. what happened on the day in january when apple hit $93? the company reported a monster quarter best ever, but the analysts chose to focus on how it would be the last good quarter for iphone sales, and therefore apple's earnings were all downhill from there. one analyst after another cut the price target. if you look back, the forecast for an endless amount of -- >> the house of pain. >> as this one-trick pony was finally exhausted. it made you feel like you should just shoot the darn thing to put it out of is misery. the call to trade apple was in the air, as usual. trade out of it! you can always get back into it. there's always that ability to say, hey, catch you lower later, alligator, but you didn't get to

catch apple lower, the 93 was the low of the year. the stock has been rallying ever since. investors realized next quarter would likely be the low, and apple now is a terrific $20 pill onrevenue stream. just check crier itunes, your i cloud or app store bill, if you even bother to read it, so maybe it's not that big for you, but you've got a billion people owning apple devices, the service charles, they add up, for apple. the bottom of apple's stoke coincided with the bottom of china's stock market. everyone was so worried at the time about slowing chinese sales, how about chevron, one of the largest oil companies in the world. on january 20th, oil fell for $26.50. chevron stock pulled back to $78

and change. good time to sell? >> sell sell sell. >> how about looking at it like this? when oil broke through from 40 to 39 on the way to 26.50, chevron had been trading at 69. that's right, chevron stock was literally nine points lower when oil was $13 higher. i know it was tough to bike that stock in the last week of january, but the fact that it was substantially higher showed you that the company did have the wherewithal to hang in there. so chevron was a buy, not a sell. when it was yielding 5.4%. this is one that -- this is really -- this is really the mrs. hafersham tell. what was going on? you could look at it one way, one is that wynn would never recover from the relentless decline in gambling in macau.

yo can it was about to open a brand-new casino there, or maybe a better way, the founder and ceo, what did he do? as followed by another $15 million purchase. that's on top of the 63.8 million of insider buying in december. all because he said the opportunity was great to endure, he was very aingely at the chinese government. not only can wynn make no secret of one of the biggest insider buys, but pretty much taunted those who were against him i love that guy. then there's adobe and salesforce.com. two companies that came in on the week that linked in and --

cratered. their from the pin action from linked in and simple data. salesforce falling for 53, adoblest sinking to 73. if you refused to panic, these were amazing buying opportunities. salesforce surged back to 74, adobe now at 94, thanks to the great quarters. here's within last example. in the second week of february, european banks with are teeth elering, oil was plummeted, averaging down double digits, and despite having zero exposure, except as a beneficiary of cheaper oil, it felt from 133 to 111. is it any wonder that home depot has rallied back, with a round trip amassing as it was, yes, predictable? in each of these instances it seemed like plenty of reason to bail. yet companies have reasons to be

encouraged. apple explaining it wasn't one product, or steve wynn shelling out $110 million to do some insider buying. bottom line, please remember even if you hate the market, and boy, do i know a lot of people who do, there is almost always a better time to ring the register on stocks of great companies than into a maelstrom of panic, because panic is not a strategy. mark in washington, d.c., mark? >> caller: boo-yah, jim. >> be there soon. a big dinner coming up. >> caller: concern chipotle how would you trade the earnings? >> they have already preannounced. i think things have gotten better. i won't be sidetracked by this better burger thing. anytime it's until 450, i think you buy it. i think that 18 months from now

we'll look back and say what was wrong? six months from now, we'll sigh gu geez, i should have gotten in. why don't we go to joe in my home state of new jersey. joe? >> caller: heo, cramer. >> what's shakin'? >> caller: thanks for all that you do i own a lot of the stocks and every year i always beat the dow jones benchmark and this year they're up over 10%. thanks again. >> thank you. >> caller: my stock is general mills, and they beat on earnings, but missed on revenue. what do i do? >> listen and listen good, gull you're a fellow new jersey-illustrate. general mills is run by ken

pall, and that is up he's consistently raised the different. he buys back stock. it is a marvel, and it will stay a marvel. don't touch it. if it goes below 60, buy it. susan in massachusetts, susan! >> caller: hey, cramer, i'm calling about celgene. i'm a longtime buyer. i tonight a gain of like 65%, i took a small portion of that gain and bought it, and now it's down 17%. i'm trying to decide what to do. >> we don't where stocks come from, we care where it's going to. i think celgene is very inexpensive. bob he did step down from ceo, and it made me less aggressive. why? i i think the word of bob, but it is an expensive stock. sure, sometimes there are reasons to bail, but panic is

not a strategy, people. there's always a better time to sell. radius health was once viewed as one of the most promising members of the ipo class in 2014, but down nearly 50% so far this year. is it time to reconsider? i've got the ceo. wondering what's driving this run to all-time highs in many industrials? i'm calling on the sherlock holmes of this market to find out. and there are grim days for biotechs, could a company fighting super-infections be worth speculating on? i've got the ceo. why don't you stick with cramer. don't miss a second of "mad money." follow @jimcramer on twitter. have a question, twe tweetweet #matt mad tweets, or give us a call. missomething in head to

madmoney.cnbc.com.

with most of the biotech cohort rebounding on the news of a takeover bid looming, what

what you to make of radius health with the stock that was actually down today. and put through the meat grinder, along with the rest of the biotech cohorts. nothing to do with radius specifically. we just got really good news. it filed a new drug application for the lead drug, a promising therapy for osteoporosis that's always awaiting regulatory review in europe. but today came back both of those gains, investors swapped. where it's speculating on, particularly given that there could be a major potential drug approval, let's take a closer look at bob ward, the president and ceo, learn more about how

the company is doing. welcome bag to "mad money." good to see you. have a seat. this is a huge study. this is not just 10 or 50 people. this is a giant amount of evidence you gave the fda yes. >> in the active stephen, 2,400 patients, 30 clinical sites in 20 different countries. so getting the nda submitted is a big de-risking event for radius. we have a terrifically strong balance sheet, a great team, so a very exciting year for us. >> the results versus what's out there right now seems pretty darn more effective. >> we had an active compare tore, so we're pleased that the profile is available >> i'm glad you're here. i have found that the analysts, and -- as the stock goes down, they find reasons not to --

downgrade to hold, saying there's given the lack of practical advantages and little different jails. that's certainly not what the data has at least shown. not many people realize there are more americans -- >> 1.5 million. >> fractures last year, but if we had a heart attack, the odds would great treated very, very high. two thirds of the patients are diagnosed and treated, so it's a huge unmet medical need. as new therapies come out, it readdresses this question, how do we get access? and how do we get -- >> even more -- the patients who had a hip fracture, most of them have had a fragility fracture earlier. this would mean to me that the patient population could be even bigger than the people in the hospital with hip fracture.

>> you're right, jim. story process is an unmet medical need where the patient numbers are measured in millions. >> again, when the stock goes down, people are looking for explanation. you also have another drug for a hot flag. where is that? >> our program, we're fully enrolling a face 2-b trial. that started in december last year. >> our breast cancer program, face 1 dose escalation ongoing, that will soon go into expansion cohorts, but remember, jim, the nda submission de-risks the company and in many ways it's a triggering around partnering. >> i think some of you wanted to name a partner, but that's not the way you play. >> we've said we're pleased with

the progress and we've been asked why are you continuing to negotiate? because the slice of the pie on our side of the table has been getting bigger, as derisked information becomes available. >> you have the money to hold out. >> we're well financed and not looking to raise more money at this time. >> that's what's really important. bob ward. president of radius health. even when the best news isn't helping, but one day it will. "mad money" is back after this. coming up, cramer dives further into the better boy tech space with a company trying to defeat the scourge of hospital-borne super-bugs. are you eyes the wrong investment? cramer offers the warning, just ahead.

wrely on the us postal service? because when they ship with us, their business becomes our business. that's why we make more e-commerce deliveries to homes than anyone else in the country. here, there, everywhere. united states postal service priority: you

before the band separated over unknown creative differences. [ crash ] and reunited three decades later for a tour that sold out in three minutes.

and your cisco hybrid cloud handled millions of ticket orders without breaking a sweat. before all of this, [ crash ] the experts at cdw orchestrated a cisco hybrid cloud solution. s orchestration by cdw. . you know me. i like to poke fun at the huge cohort of analysts who don't bother to think past the next quarter or even quarter of an hour. i find most of the calls too fleeting to be useful for all but the quickest of hedge fund managers. but when i see a piece of research that is terrific that can help you make money, i want to shout it out from the rooftops, which brings me to an eye on the market newsletter by jpmorgan asset management which i saved from april 1st of 2015,

where he said it was time to turn bullish on europe. a brief note on the european mini-renaissance, it talk but how there were signs that he saw and yet no one was paying attention, probably because everyone wall street sec -- probably because of the soap opera of greece. i've been reading him for years. he been the sippingle biggest bear in europe when he wrote a legendary sick men of greece. one year ago at the precise moment when pretty much everyone else had given up on the idea that anything could save the continent he drilled down on the actions that mario draghi was taking and saidy we the going to take root. he cited the facts that interest rates and mortgage rates had plummeted which would he took a hard look at how the surveyses

like the p. mi composite had turned up and measured european confidence, and he checked retail sales and most importantly car registration. the conclusion -- every one of these indicators was flashing green, but if you read other research reports and news published contemporaneously, it's good that the short-termers weren't seeing any of this, because the simple small country, greece was grabbing the headlines, but greece would coop be resewed. cembalest wrote -- when the stars aligned for mini renaissance in european economic data and for financial market changes advise expectations to have powerful consequences, end quote. sure enough, boy, that forecast is looking pretty brilliant, because the consequences have been powerful. you see, one year ago, one year ago right now, the euro hit its low. i like to measure the europo by

looks at the etf that reflects the price again -- and bean they can it was at 104. the big plunge that would take the euro it well below to the power of the greenback. they were dead wrong, he was dead right. starting next week, we'll have easy comparisons when company support, because the impossible has occurred. europe's come back. it's strong, its currency is therefore strong. we are weaker, therefore our currency is weaker. it's the beginning of the end of the super-freaking dollar's t n tyranny. those of you who are astonished at this turn of good fortune, let me admonish you. there's nothing astonishs at all. let me give you the bottom line, the unemotional detective work, it was there, yet only one sherlock holmes was able to see

it mike at cembalest. that's what's driving so many u.s.-based industrial stocks to their run to new highs right now. let's go to nate in california. nate? >> caller: cramer, what's the haps? >> what's happening? >> caller: a two part questions. >> two parts, guys quell first, underarmour just stole curl are from nike. morgan stanley butt a whopping billion on his head. is that huge number monetizable by underarmour? secondly, if you think it is, is underar more a good time to get? >> i think it's a technology company masquerading as a clothing company. that presumes that steph curry will be the michael jordan, because that franchise is unbelievable still. i question the calculations.

while i leave steph curry, i'm going to say it right northeasterly, there's only one michael jordan. there. okay. bob in new jersey, bock? >> caller: boo-yah, jim. superman versus batman, chrysler versus ford. which if either of the two is a better buy? >> oh, man, i was thinking about green lantern. hey, thinks kirby's fourth world right here. i think ford is less expensive, i also like that yield, and i think that mark fields is terrific. just for the record i'm more of a dc comics guy, so i get that? i like that comparison thatten i am -- except for jessica jones. if she were involved, that would be the winner. putting it out there. joe in ohio, joe? >> caller: hey, jim, thanks for taking my call. a big boo-yah from ohio. >> let's go.

what's happening? >> caller: awesome. my regards is lmt. do you still see it continuing a helium like -- >> we don't care about the helium thing. what steams me is people are still thinking they got picked off. they did pay too much for sikorsky, but it's been in the doghouse for long enough. lockheed matteren a big charitable trust name, and therefore i invite marillyn hewson, the ceo, to come on "mad money" and talk about lockheed martin. europe's come back, we are weaker, the evidence was there, it just took a careful eye to see the forces driving the u.s. industrials higher and therefore the euro higher. all right. hey, "mad money" -- working to take out the super bugs wreaking havoc in the hospitals, but it's another stock that's been a victim of the decline. it's not the only thing that's -- a cloud has been cast upon the entire group.

are there any remedies in sight? don't take a move. you have to hear my take on this things and rapid-fire, a special edition of "the lightning round." stick with cramer.

thank you. ordering chinese food is a very predictable experience. i order b14. i get b14. no surprises. buying business internet, on the other hand, can be a roller coaster white knuckle thrill ride.

you're promised one speed. but do you consistently get it? you do with comcast business. it's reliable. just like kung pao fish. thank you, ping. reliably fast internet starts at $59.95 a month. comcast business. built for business. is it time to reevaluate the higher risk biotech stocks that have been punished so brightally over the last six month? why it's important to be very, very careful when you're speculating. right now, i want to zoom in on a particular stock that's been a real punching bag of late. i'm talking about mcrb, series has a unique trash. normally when the bacterial ecosystem is in balance, that's

severalally your health. sometimes they can be imbalanced. it's there to that makes it home in your intestines. ed lead compound is -- cbi, inflammation of the large intestines one of the worst antibiotic-resist president threats out there. it can be treated with antibioticses, but then that causes the bacterial imbalance that -- anyone who has had a parent or older person knows exactly what i'm talking about. this is an early-stage story, series came public last june, spiked 185% on the first day of trading, since then it's been steadily downhill with the stock getting clobbered. trading down to $26 as of today. still there's reason to hope, including a partnership, that's announced back in january, could be worth up to 1.9 billion,

considering series has a market cap of just a billion, let's check in with roger pop rants, the chairman, president and ceo of series therapeutics, dr. pop rants, welcome back. >> it's great to be invited back. >> i mentioned that for elderly or parents, kids who have parents that got -- you know this is the trade-off. they say we've got the thing, it's absolutely terrific. unfortunately it will destroy another part. you have something that doesn't necessarily have the unfortunate part to it. >> that's exactly right, jim. in your intestine, trillions of bacteria that are really part of you. you don't have a colon without a trillion of bacteria. when you kill those off, even if you kit off cdif, you el leave your self-open for other -- what we do at seres, we replace and reconstitute that so you now have a normal organ again.

>> i think we have to change the dynamic of how we talk about drugs. this is kind a natural things that would save the system really maybe hundreds of millions of dollars, and per patient it's just extraordinary how much it costs, and yet you can still make good money. >> absolutely. we walk in every day and think about the patient, but at the same time we think about how we can save money for a failing health system, and we can do both. how do you do that? you go to high on medical need niche, in this case recurrent cdi, you come up with a drug that's innovative with tremendous data, and then you use it and price it radio i got so you can make a fair profit for your shareholders at the same time returning money to the failing health care system. we can do that in this. we've looked at it from the beginning. we believe it is a win-win. this is what drug development is or should be about. >> that's what interested me about nesly, i don't think it

would be involved nfc it is a natural compound. in your natural evolutionary train of thought, walk us through it, because i think it's also why nestle might have been interested. >> it's not unusual. it is based on clear medical principles. this ordinary-looking tree is very ordinary-looking. i took this picture myself in ghana, west africa. >> good photography. >> not bad. this tree is one of the most famous trees on the planet. it was called the fever tree. it's really a cinkona treat. for generations, in order to treat malaria, you would scrape this bark, making tea, and you would get better. then when we learned what's the active agent, and that happened in the last century, it turned out to be something called quinine. the first anti-ma larial drugs.

that's what we do. we isolate what's missing, develop a clear, well characterized drug, it becomes like quinine. >> okay, so let's follow up again. nestle calls you, they read your stuff and they want we want to partner, because this is a natural solution that's kind of nestle's way? >> absolutely. when we heard from nestle health sciences. >> which is pretty amazing. >> i think they're getting into how you use natural approaches, like the cincona trees, like the microbiome, to make active drugs. what does this mean? they wanted to work with us. we want to do laumplg this drug in the u.s. ourselves. we can do that, orphan disease. i've done it before in hiv, but we did a deal for the rest of the world. we're ambitious, but not crazy. we believe this drug is for every patient around the world with c-dif, it's a change in the

paradigm. working with nestle health sciences, they have the global reach, the ability to get to every patient in a rapid but safe manner. that's our goal. >> it's important for people at home, this is speculative, but the price has come down, necessarily's is willing to partner with them for a price that says the whole company has to be worth more than it's selling, and we really only talked about one of many drugs. that's dr. roger pop rants, the chairman and president of mcrb. "mad money" is back after the break.

it is time. itis time for "the lightning round." rapid-fire questions, and then lloyd lloyd is over. are you ready, skee-daddy? let 'start with benet. >> caller: what do you think about relipsa? >> no, no, no, too speculative.

didn't like the last results. i know many viewers love it, and they're giving me heck, but i have right to be cautious brian in michigan? brian. >> caller: boo-yah, brother. >> i'm looking to buy wwe, wrestle mania week. what's your take? >> not enough there. we've got entertainment companies like disney and time warner, those i like. how about james in south carolina? james? >> caller: thank you for taking my call. i'd like your opinion on corvo? >> no. we have broadcom, and skyworks. i think both are doing better. i need to go to jerry in wisconsin. jerry? >> caller: hi, j.p., thanks for taking my call. >> no promise. >> caller: any suggestions on shake shack? >> here's my problem with shake shack. it's too expensive per store unit. i pressure mcdonald's not the

burgers, though i have to tell you i think the egg mcmuffin gives every bit shake shack a run for their money. steve in new jersey? >> caller: i love your show. i have a traditional i.r.a. and a stock called -- ier -- >> no, no, no. that is a huge yield. i've got to tell you, that is a total red flag, and i'm not playing. i don't need that. when i see that, that's a red flag, i'm not playing. can we take one more? i'd like to go to stan in florida. stan? >> caller: jim, listen, i'm interested in a small biotech, with a different way of treating tumors. nova-cure. >> i would have to do my work. it's down huge. maybe they have something new. i have to do my homework. ladies and gentlemen, that is the conclusion of "the lightning round." "the lightning round" is

response soyed by -- -- sponsored by -- ♪ ♪ for your retirement, you want to celebrate the little things, because they're big to you. and that is why you invest. the best returns aren't just measured in dollars. td ameritrade®.

great time for a shiny floor wax, no? not if you just put the finishing touches on your latest masterpiece. timing's important. comcast business knows that. that's why you can schedule an installation at a time that works for you. even late at night, or on the weekend, if that's what you need. because you have enough to worry about. i did not see that coming. don't deal with disruptions. get better internet installed on your schedule. comcast business. built for business.

on a day where we've interviewed two ceo of rather speculative biotech companies, i've got to do some work here. i think it's worth reminding you of a major caveat. the entire groups is full of land mines, given that the ibb,

the nasdaq biotech eff is down an astounding 23% year to date. even after all the marks has done to come back. i would rather by a buyer. in many cases it's way too late to get out. so many people have hi the eject bussen that the group seems sold out to me. we saw some of a run today. but you need to be careful when you're speculating. this is an incredibly volatile sector where eve blow up in your face, so let me give you a precautionary tale. i'm going to talk about incy and pour tolla pharmaceuticals,

ptla. they're two beaten-down biotechs that have been particularly hard hit of late, because i have to show you how quickly things can go wrong in this space. i want you to be careful. i want been to be fearful. that's right, when you're speculating, you have to be fearful. incyte, a biotech company that judd roared today, around $4 or 6%, on some strong phase 3 results from a rheumatoid arthritis therapy. however even after its rebound, incyte still lost an outstading 45% of the values since the highs at $131 in september. talk about a brutal decline, but before we getting into the reasons why. -- that only have drgsz in phase is or 2, maybe really, really

long time before they can potential hit the market. incyte, on the other hand already has a product on the market, which is approved for a rare type of bone marrow cancer that disrupts the production of blood cells, as well as another disorder that results in too many red blood cells. not only is it on the market, it is selling incredibly well. $601 million in revenues last year, up 68% from to 14. that's pretty impressive. so you think maybe it's not so speculati speculative. they have a robust pipeline with more than a dozen drugs currently in clinical trials. some -- including some exciting immunooncology developments. three drugs in face 2, a bunch of earlier stage compounds. on top of all that, incredibly lucrative partnerships. so you have the phase 3, the great partners, you've got a drug already selling a lot.

what exactly went wrong here? incyte has been publicly traded for more than to years. it was basically a non-entity until the stock took off after the jakofi got fda approval. meanwhile, we were getting results from the company's pop line. add ran up another 24%. inside ran from 73 up to $131, on the strength of the sales and the strong pipeline i mentioned, but then the stock fell off a cliff, and in less than seven mondays, part of that weekness had to do with the whole biotech industry and the pharma space, especially after hillary clinton declared her crusade against high prices.

last november incyte rolled out results from the phase 2 trial of a drug designed to prevent the growth of many kinds of tumors. the stock got slammed because the drug demonstrated a lower response rate. highly unusual. it took incyte from 115 down to 100. the stock held there for a few months, but then got obliterated on no real negative news, simply because the rest of the market was selling off the biotechs, but the final blow in january alongside strong quarterly results, it announced it was discontinuing the phase 3 trial of this pancreatic cancer drug. i was shocked. i thought this one was in the bag. i'm not kidding. i thought -- it shocked everybody. the stock settled at $65 even as analysts caused the sell-off overdone. since then it's bounced back and roared today on positive data

with the arthritis drug. but if you own incyte through this whole period, you're still hurting. what are the lessons? first, it's very difficult to value a compete. it occurrencely trades 50 times earnings estimates. so like most biotechs, it toned to trade on clinical trial data and drug approvals. when the data is good, the stock is a juggernaut, but when the environment got more different and the data stopped being perfect, investors ran. this is an portion agary tale, because incyte is a great company. it has real growth. real earnings. however, when the market turned, incyte sold off, lie it didn't have anything in the pipe. that's the real danger. next up, up, you to consider the curious tails of -- case of portola pharmaceuticals.

this is a very different highly speculative story. portola has three wholly owned drugs, kline an anticoagulant, appeared one that could prevent excessive bleeding, and a blood cancer drug that's constitutional undergo a proof of concept study. this became public in may of 2013, 14.50, and finished up more than 75%, 25 and change. while the gains were modest up 10%, oh, did this thing start roars. po are. tola with two late-tame drugs. but just like incyte, portola went so free fall. the stock managed to hang in there, but since the new year, down more than 60% to $20 and change. 6.0%. again some of this weakness is because the whoa biocohort went

out, and they got hired the most. on company announced the phase 3 results to the big anticlotting drug and the results were so disappoints that the analysts who cover the stock said the odds of this drug being a commercial success had fallen do 20%. that's awful. no wonder the drug plunged. it's a classic example of how a story that looks so intriguing can fall apart overnight. it was all about -- it was a two-legged stool, and a bad rule can kick out one of those legs in the blink of an eye. i can't so el this coming. you can't. people were shocked here. so why does anyone bother, then? why bother with speculative names given the disasters i just told you about. the flip side is just what

happened today at maker of a prostate drug that saw its stock soar 23% on takeover speculation. one session. again, though, you really need to be careful. if no takeover big materializes. you can expect the stock to give up most or maybe all of those gains. if there's a bid, then the whole group is set to soar. the bottom line -- if you're going to own early-stage biotech stocks remember they can lose a tremendous amount of value in the blink of all. it's not for the faint of heart. certainly not for your retirement fund. biotech is speculation only. the next time you think otherwise, just remember the uber-cautionary tales of incyte, and portola, what lood like a fantastic speculation. stick with cramer. and a parade rained on the sales team's parade. and they still made the meeting, without actually going to the meeting. before any of this, cdw orchestrated a mobility solution,

using the hp elite x2 1012 with intel core m vpro processors. mobility by hp. orchestration by cdw.

my pal stacy keach is back withal all-any "amecan greed." tyke it's by mayor nagin. marriott gets starwood and it's time to sell. it's all played out. i like to say there's always a bull mark somewhere. i promise to try to find it just for you right here on "mad money." i'm jim cramer. i will see you tomorrow.

>> on this episode of "secret lives of the super rich," on board one of the most extravagant mega-yachts ever built. >> you've almost convinced me that i'm getting a bargain at 200 million bucks. >> come aboard the 280-foot ship that'll make a billionaire feel like king of the sea. [ ship horn blares ] fall in love with a $22 million bel air mansion and its subterranean disco pool. >> i can immediately tell if somebody wants to have sex with the house or not, which would tell me if they want to buy it. >> 319 miles an hour. >> meet the billionaire heiress who risks it all on the drag strip. >> i just kept cutting through the air like a knife. >> and enter the $18 million